A single-arm, open label, multi-center phase I/II trial to assess the safety and efficacy of BIBF 1120 added to low-dose cytarabine in elderly patients with AML unfit for an intensive induction therapy (BIBF 1120)
Basic data for this project
Type of project: Own resources project
Duration at the University of Münster: 01/01/2010 - 01/12/2020
Description
Keywords: AML
Project management at the University of Münster
| Faldum, Andreas | Institute of Biostatistics and Clinical Research (IBKF) |
| Schliemann, Christoph | Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A) |
Research associates from the University of Münster
| Gerß, Joachim | Institute of Biostatistics and Clinical Research (IBKF) |
| Koch, Raphael | Institute of Biostatistics and Clinical Research (IBKF) |
| Urban, Marc | Center of Clinical Trials (ZKS) |